| 产品描述: | TAS0728 是一种有效的、选择性的、口服活性的、不可逆的共价结合 HER2 抑制剂,其 IC50 为13 nM。TAS0728 对于 BMX、HER4、BLK、EGFR、JAK3、SLK 和LOK 也存在抑制效果,其 IC50 值分别为 4.9、8.5、31、65、33、25 和 86 nM。此外,TAS0728 对 HER2、HER3 和下游效应蛋白的磷酸化还表现出强大而持久的抑制作用。 |
| 靶点: |
HER4 8.5 nM (IC50),HER2 13 nM (IC50),EGFR 65 nM (IC50),BMX 4.9 nM (IC50),BLK 31 nM (IC50),JAK3 33 nM (IC50),SLK 25 nM (IC50),LOK 86 nM (IC50);EGFR;HER |
| 体外研究: |
TAS0728 is a covalent-binding inhibitor of HER2 kinase and exhibits high selectivity for HER2 kinase. It also shows inhibitory activity against BMX, HER4, BLK, EGFR, JAK3, SLK, and LOK. |
| 体内研究: |
TAS0728 reveals the sustained and targeted inhibition of phosphorylation of HER2, HER3, AKT and ERK. TAS0728 also shows the ability of tumor regression and low toxicity. |
| 参考文献: |
1. Irie H, et al. TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models. Molecular cancer therapeutics. 2019;18(4):733-42. Epub 2019/02/23. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.982 ml |
9.909 ml |
19.818 ml |
| 5 mM |
0.396 ml |
1.982 ml |
3.964 ml |
| 10 mM |
0.198 ml |
0.991 ml |
1.982 ml |
| 50 mM |
0.04 ml |
0.198 ml |
0.396 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |